An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Summary

This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.

Timeline

Start

2002-10

Primary completion

2009-08

Completion

2009-08

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Gemcitabine/Carboplatin vs Paclitaxel/Carboplatin; p = 0.199; Log Rank NCT00191646 ↗

Drugs

Indications